跳至主要内容
临床试验/NCT01997749
NCT01997749已完成1 期

The Effect of a Ketogenic Diet on Blood Glucose, Function and Disease Progress in Acute Stroke Patients

University of Copenhagen2 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2013年5月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
64
试验地点
2
主要终点
Change from baseline fasting blood sugar at 7 days

研究概览

简要总结

The purpose of this controlled, randomized intervention is to investigate whether a fat-based (ketogenic) diet given for a week has a positive effect on blood sugar, mortality and function in patients hospitalized with acute stroke compared to the effect of a usual diet.

The study hypothesis is that a ketogenic diet and reduced availability of glucose to the brain cells will reduce the volume of neuronal damage in the brain and improve function.

The intervention will take place at the neurological units of Glostrup and Bispebjerg Hospital in Denmark.

详细描述

A ketogenic diet can induce ketosis after a period of 2-3 days and offer the brain an alternative energy substrate to glucose in the form of ketone bodies. Feeding the brain ketone bodies can potentially benefit a stroke patient's brain in several ways:

Stroke is characterized by impaired blood and oxygen supply to brain cells. This can cause glucose to convert to lactate which is toxic for the brain. Decreasing glucose availability to brain cells may thus potentially decrease the area of damage in the ischemic penumbra (perifephery of the stroke). Compared with sugar, burning ketone bodies requires less oxygen to produce the same amount of energy, suggesting that brain cells could have a potential greater chance of surviving during circumstances of reduced oxygen supply. By decreasing mitochondria activity, ROS synthesis is also decreased, which can help decrease the necrotic area around the ischemic penumbra. Furthermore, the ketogenic diet does not induce an increase in blood sugar which could be an advantage since many stroke patients are admitted with hyperglycemia associated with a worse outcome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with ischemic or hemorrhagic stroke.
  • NIHSS score of at least
  • Both primary and recurrent cases.
  • Inclusion as early as possible, but no later than 72 hours from symptom onset.
  • Patients with expected hospitalization for a minimum of seven days.
  • Adult patients with cognitive ability to give informed consent.
  • Patients with writing and orally accepted participation.

排除标准

  • Patients with SAH and traumatic hematoma.
  • Patients with pancreatic insufficiency (steatorrhea).
  • Patients unable to give informed consent.

结局指标

主要结局

Change from baseline fasting blood sugar at 7 days

时间窗: Baseline and 7 days

Change from baseline p-C-peptide at 7 days

时间窗: Baseline and 7 days

Change from baseline NIHSS (national institute of health stroke scale) at 90 days

时间窗: Baseline and 90 days

NIHSS is a common stroke scale used to objectively quantify the impairment caused by a stroke

次要结局

  • Change from baseline p-CRP at 7 days(Baseline and 7 days)
  • Change from baseline p-potassium at 7 days(Baseline and 7 days)
  • Change from baseline p-LDL at 7 days(Baseline and 7 days)
  • Number of patients who died (mortality)(up to 3 months)
  • Number of patients with pneunomia(Up to one week)
  • Change from baseline p-bilirubine at 7 days(baseline and 7 days)
  • Change from baseline p-beta-hydroxy butyrate at 7 days(Baseline and 7 days)
  • Change from baseline p-ALAT at 7 days(Baseline and 7 days)
  • Change from baseline INR at 7 days(baseline and 7 days)
  • Change from baseline p-triglyceride (fasting) at 7 days(Baseline and 7 days)
  • Change from baseline p-alkaline phosphatase at 7 days(baseline and 7 days)
  • Change from baseline p-phosphate at 7 days(Baseline and 7 days)
  • Change from baseline urine-ketones at 7 days(Baseline and 7 days)
  • Number of patients with gastrointestinal complications(Up to one week)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Arne Astrup

Dr.Med.Sci./Ph.D.

University of Copenhagen

研究点 (2)

Loading locations...

相似试验